CALVIVE

Adults and children: 1000mg per day. The effervescent tablets should be dissolved in a glass of water (approx. 200 ml) and drunk immediately. Calvive 1000 effervescent tablet may be taken with or without food.

Adverse reactions are listed below, by system organ class and frequency. Frequencies are defined as: uncommon (>1/1,000, <1/100), rare (>1/10,000, <1/1,000) or very rare (<1/10,000), including isolated reports.

Immune system disorders:

Rare: Hypersensitivity, such as rash, pruritus, urticaria.

Very rare:

Isolated cases of systemic allergic reactions (anaphylactic reaction, face oedema, angioneurotic oedema) have been reported Metabolism and nutrition disorders: Uncommon: Hypercalcaemia, hypercalciuria Gastrointestinal disorders: Rare: flatulence, constipation, diarrhoea, nausea, vomiting, abdominal pain Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard.

5 mmol/24 hours), or with a history of urinary calculi, monitoring of calcium excretion in the urine is required. If necessary, the calcium dose should be reduced or therapy should be discontinued. An increased fluid intake is recommended for patients prone to formation of calculi in the urinary tract.

In patients with impaired renal function, calcium salts should be taken under medical supervision with monitoring of calcium and phosphate serum levels. During high dose therapy and especially during concomitant treatment with vitamin D, there is a risk of hypercalcaemia with subsequent kidney function impairment.

In these patients serum calcium levels should be followed and renal function should be monitored. There have been literature reports alluding to possible increased absorption of aluminium with citrate salts. 0 mg of citric acid) should be used with caution in patients with severely impaired renal function, especially those also receiving aluminium-containing preparations.

Calvive 1000 effervescent tablet contains aspartame, sodium, sorbitol, benzyl alcohol, sulphur dioxide and glucose This medicine contains 630 microgram sorbitol (E 420) in each tablet. 9 % of the WHO recommended maximum daily intake of 2 g sodium for an adult.

This medicine contains 180 nanogram benzyl alcohol in each tablet. Benzyl alcohol may cause allergic reactions. Increased risk due to accumulation in young children. High volumes should be used with caution and only if necessary, especially in subjects with liver or kidney impairment because of the risk of accumulation and toxicity (metabolic acidosis).

This medicine contains 210 nanogram sulphur dioxide that may rarely cause severe hypersensitivity reactions and bronchospasm. This medicine contains 30 mg aspartame in each effervescent tablet. Aspartame is a source of phenylalanine, and may be harmful for people with phenylketonuria.

1 of the effervescent tablet - Diseases and/or conditions resulting in hypercalcaemia and/or hypercalciuria - Nephrocalcinosis, nephrolithiasis